Moderate-to-heavy Alcohol Consumption in Young Adulthood May Lead to Early Stroke, Warn New Study Findings
Study authors saw a positive dose-response relationship driven by hemorrhagic stroke in young adults who were moderate-to-heavy drinkers in their 20s and 30s.
CDC Releases Updated, Expanded Clinical Guidance on Prescribing Opioids for Pain
The 2022 guidance covers acute, subacute, and chronic pain and replaces the 2016 guidelines.
Remote Electrical Neuromodulation Device Effective for Migraine Prevention in Pivotal Trial
The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.
Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
AACE President Sethu Reddy, MD, Highlights Updated 2022 Diabetes Guidelines for Primary Care
Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.
Daily Dose: Weight Loss Management in Primary Care
Your daily dose of clinical news you may have missed.
OTC Progestin Only Pill Could Prevent Up to 30k Unintended Pregnancies in the US Annually: Modeling Study
An OTC progestin only pill could potentially reduce the number of annual unintended pregnancies in the US by tens of thousands, a novel modeling study reveals.
Study: “Worrisome” Changes in Cardiovascular Function Immediately after Vaping, Smoking Traditional Cigarettes
AHA 2022: Chronic users of either e-cigarettes or traditional cigarettes had acute changes in cardiovascular function and performed worse on exercise stress testing than never users in new study.
Apixaban May be the Safer DOAC in Afib, Suggests First Large Comparative Analysis
Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.
7 RSV Myths and Facts: Prepare for the New Wave of Misinformation
RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.
Daily Dose: Efficacy of Maternal RSV Vaccine
Semaglutide 2.4 mg (Wegovy) Yields "Amazing" Weight Loss in Adolescents, Similar to Adult Response
Semaglutide 2.4 mg (Wegovy) weight loss benefits in adolescents mirror those seen in adults, according to phase 3a trial findings presented at ObesityWeek® 2022.
Pharmacologic Interventions for Adults with Obesity: Guideline Topline for Primary Care
The American Gastroenterological Association released its first medical guideline recommending prescription medications for weight loss in adults with obesity. A review, here.
Practice-related Factors in Primary Care May Limit Weight Management Services Offered
ObesityWeek® 2022. Primary care clinicians report providing on average just 70% of a wide range of clinical weight management services, according to a new survey.
Daily Dose: Blood Pressure Control Declined during Early Months of Pandemic
Wearable Device Uptake Low Among Adults with Cardiovascular Disease, Nationally Representative Study Finds
AHA 2022: An estimated 18% of Americans with heart disease reported using wearables, compared with 29% of the total US population.
RSV Older Adult Vaccine Candidate from GSK Wins FDA Priority Review, PDUFA Date Set
The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.
Maternal RSV Vaccine Prevents Infection in Infants, Pfizer Announces
Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.
Tirzepatide Associated with More Weight Loss than Placebo Regardless of Obesity-related Comorbidities, New Research Finds
ObesityWeek 2022: Regardless of the number of obesity-related comorbidities, tirzepatide was associated with a greater reduction in body weight than placebo.
Early Months of COVID-19 Associated with Worsening BP Outcomes in Adults with Hypertension, New Study Finds
Use of telemedicine and home blood pressure monitoring may mitigate adverse impact on BP control during future large-scale emergencies, noted researchers.
